American Society of Hematology Annual Meeting 2020
Welcome to Elsevier’s ASH Annual Meeting site. Here you can learn about our hematology journals, browse through our free article collection and highlighted special issue, and find out more about Elsevier's Oncology Journal Network.
ASH Publishing Partnership
Elsevier is delighted to announce a new partnership with ASH, the top society in the field of hematology, to publish Blood and Blood Advances from January 2021. The Society’s partnership with Elsevier will support its mission to promote research, clinical care, education, training, and advocacy throughout the global hematology community. For more information, please view the full partnership announcement here.
With an Impact Factor of 17.794 (2019), Blood is the most highly cited peer-reviewed publication in the field of hematology. It provides an international forum for the publication of original articles describing basic laboratory, translational and clinical investigations in hematology. Launched in 2016, Blood Advances is a semimonthly online-journal that publishes peer-reviewed original articles, which are open for all to read. Blood Advances already has an impact factor of 4.910.
Elsevier looks forward to welcoming these two journals as the centerpiece of our hematology program starting in 2021.
From January 2021
Free Access to Select Articles From Our Hematology Journals
With a variety of titles to choose from, your journey to publication starts here:
In this curated collection, we highlight the latest developments in the hematology field. All of the articles are free to access until March 31st, 2021:
- Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis
- Mantle cell lymphoma
- The opportunistic effect of exosomes on Non-Hodgkin Lymphoma microenvironment modulation
- Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models
- Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies
- Will CAR T cell therapy have a role in AML? Promises and pitfalls
- Immune reconstitution after T-cell replete HLA-haploidentical transplantation
- The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future
- Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide
- A Narrative Review on Hospital-Acquired Anemia: Keeping Blood where It Belongs
- Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis
- Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism
- Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer
- Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice
- Venetoclax: A new wave in hematooncology
- CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy
- Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
- Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
- Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
Thrombosis Update is an International Open Access journal publishing basic, translational and clinical research in vascular biology, thrombosis and hemostasis. Thrombosis Update is a companion Journal to Thrombosis Research and will also publish novel cellular and molecular studies and new developments in the diagnosis, therapy, prognosis of thrombotic and vascular diseases. The journal publishes high quality original research, review articles, case reports and brief communications.
Transplantation and Cellular Therapy (2021 title change from Biology of Blood and Marrow Transplantation)
For a number of years, ASTCT (formerly ASBMT) has worked to improve our journal. That’s why we’re excited to announce the new name of our journal: TCT: Transplantation and Cellular Therapy. This new name will come with a new look and represents the natural step forward we've seen in the field and within our own organization and aligns with the name of our society.
While blood and marrow transplantation is still the foundation that this journal is built upon, we realize that the developments in other types of cellular therapies propel our community forward. We want to be a home base for people to share critical information about all types of cellular therapy—from both transplant and non-transplant cellular immunotherapies. As our society and medicine evolve, we want to be at the forefront of what is happening. While the new look and format is different, rest assured the quality of science will continue to excel.
2020 Special Issue: Clonal Hematopoiesis published in Experimental Hematology
In this special issue of Experimental Hematology, we are excited to present 11 articles that provide different insights into and perspectives on the history, current status, and new developments in CH/CHIP research. Although our understanding of clonal hematopoiesis, how it develops, and its implications for human biology and disease is still at an early stage, many intriguing approaches are now moving this field forward.
Elsevier’s Oncology Journal Network
We’ll help you find the right home for your research – fast
Publishing your work can be time-consuming, especially if the first journal you submit to isn’t right for your research. With over 40 journals, including The Lancet Oncology, Cancer Cell, European Journal of Cancer and Cancer Letters, Elsevier’s Oncology Journal Network has the right home for your research. And with our transfer service, you’ll benefit from a smooth, simple publishing process.